Bristol Myers and Hengrui sign $15.2B multi-asset biotech collaboration

The deal covers 13 early-stage oncology, hematology, and immunology programs, making it one of the largest China–global biotech alliances to date

$BMY and Hengrui signed a $15.2B multi‑asset global collaboration, covering 13 early‑stage programs across oncology, hematology, and immunology — one of the largest China–global biotech alliances to date. https:// prnewswire.com/news-rel